PolyPid Ltd. (PYPD), an Israel-based clinical-stage specialty pharmaceutical company, is a highly innovative company specializing in the development and manufacturing of extended-release drugs. The company's primary focus is on creating post-surgery therapeutics designed to improve surgical outcomes. The company operates with the mission to improve patient outcomes in the fields of surgery and oncology, demonstrating its commitment through innovative drug development.
The key technology platform at the nucleus of PolyPid's operations is the PLEX (Polymer-Lipid Encapsulation matriX) technology. This unique combination of polymers and lipids enables the controlled and continuous release of drugs over extended periods, ranging from days to several months. The PLEX platform has been used to develop a growing portfolio of products, impressive in both its reach and diversity, targeting a variety of healthcare sectors, such as orthopedics, colorectal, and surgical site infections.
Arguably, the most notable of these products is D-PLEX100, which has completed Phase 3 clinical trials and is expected to apply for a New Drug Application with the U.S. Food and Drug Administration. D-PLEX100 is aimed at preventing surgical site infections (SSIs), which are a significant cause of morbidity, prolonged hospitalization, and even death following surgery. In several clinical studies, D-PLEX100 has demonstrated a significant reduction in SSIs.
In addition to D-PLEX100, PolyPid is working on a number of other promising drug candidates for various applications, including bone void infection and intra-abdominal infections, among others.
Founded in 2008, PolyPid has gone public in 2020 and is listed on NASDAQ under the symbol "PYPD". The company's management team is comprised of experienced industry professionals who demonstrated a solid history of success in the pharmaceutical industry, united in their quest to curb complications in the surgical landscape.
Despite being a relatively young company, PolyPid has established a strong foothold in the healthcare industry. Its commitment to innovation, improving patient outcomes, and addressing unmet medical needs, firmly positions PolyPid Ltd as a substantial and promising player in the world of specialty pharmaceuticals.